Available online on https://ijarms.com

International Journal of Advance Research in Medical Science 2025; 1(2):19-26

(Review Article)

Artificial Intelligence in Pharmaceutical Science: Revolutionizing Drug Discovery and Healthcare Delivery

Janvi Jain[1], Harshita Badoliya[1], Vartika[1], Firoj Tanwar[2], Shabana Zaffar[2]

[1]Scholar, Arya College of Pharmacy, Jaipur, Rajasthan

[2]Assistant Professor, Arya College of Pharmacy, Jaipur, Rajasthan

Received: 10/05/2025/ Revised: 25/05/2025/ Accepted: 14-06-2025

Corresponding Author: Janvi Jain

Conflict of interest: Nil

Abstract

The use of artificial intelligence (AI) in medicine, especially through machine learning (ML), represents a major advancement in drug discovery. AI serves as a strong tool that helps bridge the gap between understanding diseases and identifying possible treatments.

Drug development is costly, takes a lot of time, and has a high rate of failure. In recent years, artificial intelligence (AI) has become a game-changing tool in drug discovery, providing innovative solutions to complex problems in the pharmaceutical industry. This document discusses the various roles of AI in drug discovery, including AI-assisted drug delivery design, finding new drugs, and developing new AI techniques.

We look at the different stages of the drug discovery process, starting from identifying diseases and covering diagnosis, target identification, screening, and lead discovery. AI's ability to analyse large datasets and recognize patterns is crucial in these stages, improving predictions and efficiencies in disease identification, drug discovery, and managing clinical trials. The importance of AI in speeding up drug development is highlighted, showing its potential to analyze large volumes of data, which helps reduce the time and costs involved in bringing new drugs to market.

Machine learning algorithms help in designing experiments and can predict how drugs are processed in the body and their toxicity. This ability allows for the prioritization and optimization of lead compounds, minimizing the need for extensive and expensive animal testing. AI algorithms can also support personalized medicine approaches by analyzing real-world patient data, leading to more effective treatment outcomes and better patient adherence. This review offers a comprehensive overview of the recent developments in AI and its role in drug discovery.

Keywords: Artificial Intelligence, Machine Learning, Disease Identification, Drug Design, Drug Discovery, Drug Repurposing.

INTRODUCTION

The traditional drug discovery process is complicated and difficult, often taking up to 15 years and costing between $1 to $2 billion for each drug that gets approved. This long timeline is mainly due to increasing rates of failure and lengthy clinical trials. Even with significant investments in resources, nearly 90% of potential drug candidates do not succeed, even after reaching phase-I clinical trials.

Getting a drug candidate to phase-I clinical trials after thorough optimization during the preclinical stage is seen as a major achievement for both pharmaceutical companies and academic institutions. Large-scale computer-based screening and docking techniques have been used to improve the success rate of lead compounds in clinical trials. However, these methods have their drawbacks, including inefficiency and lack of accuracy.

To address these issues, deep learning (DL) and machine learning (ML) algorithms, which are types of artificial intelligence (AI), have been recognized as possible solution.

The integration of artificial intelligence (AI) is set to significantly change how the pharmaceutical sector manages its supply chain operations. It also brings together various AI research initiatives from recent years to develop effective solutions for a range of supply chain challenges. Furthermore, the research points out potential areas for future investigation that could improve decision-making tools in supply chain management.

There is a noticeable lack of innovation in trial models, necessitating the reworking and repetition of ongoing projects. In the healthcare field, critical aspects such as patient recruitment, enrollment, monitoring, retention, and medication adherence need focused attention due to the nature of clinical trials. The process of enrolling patients is hindered by the travel required to trial sites, which can be time-consuming, and frequent visits contribute to the challenges of patient re-enrollment.

Utilizing AI in study design aids in optimizing and enhancing the creation of patient-centered designs.

AI employs methods to gather the vast amounts of data generated during clinical trials, thereby minimizing the workforce needed for data management. These technologies leverage body sensors and wearable devices to monitor patients' vital signs and other essential information remotely, fulfilling the need for regular face-to-face interactions (figure1).

The historical context of artificial intelligence (AI) in healthcare illustrates a gradual evolution from initial explorations to the present-day utilization of advanced AI applications across various healthcare domains. As AI technologies progress, they have the potential to redefine the future of medicine and transform healthcare practices, benefiting both patients and healthcare providers.

In recent years, there has been a significant increase in the volume of published research on AI, with a remarkable peak of 348,684 papers released in 2023. Additionally, the field of AI-assisted material discovery in drug delivery has seen a rise in publications, reaching a high of 1,234 papers in 2022. Similarly, the number of papers focusing on AI in medicine has surged, peaking at 188,845 papers in 2021. This upward trend in published research indicates a growing interest in AI technologies and suggests that more investigations are being undertaken in this field.



Figure 1: AI Solution to the Pharmaceutical Industry's

AI for New Drug Discovery:

In the field of medicine, AI applications can be categorized into two types: physical and virtual. Physical applications include technologies such as robot-assisted surgery, AI-enhanced prosthetics, real-time patient monitoring, and automated laboratory processes.

For instance, in robot-assisted surgery, AI can provide healthcare professionals with important information that helps them make better decisions. Although AI cannot replace doctors, it can significantly enhance their abilities and improve the quality of patient care. AI-powered surgical robots allow surgeons to carry out complex procedures with increased precision, control, and flexibility. This technology can lower the chances of complications, reduce invasiveness, and speed up recovery times, resulting in improved surgical results.

On the other hand, AI-driven prosthetics are designed to adjust to the user's movements and respond to their neural signals, making them more effective and user-friendly.

Drug discovery and development fall under the category of virtual applications, which also includes diagnostic assistance, personalized treatment plans, and virtual health assistants. Virtual AI applications support healthcare professionals in diagnosing diseases more accurately and efficiently.

AI algorithms can analyze medical imaging data, such as X-rays, CT scans, and MRI images, to identify abnormalities and assist in the early detection of diseases. This capability significantly reduces the chances of misdiagnosis and contributes to better patient outcomes. The strength of AI lies in its ability to process and analyze vast amounts of medical data, identifying patterns that may not be easily noticeable to humans. By doing this, AI can enhance diagnostic accuracy and aid in the creation of personalized treatment plans.

AI in drug discovery implies several critical functions that enhance the efficiency and effectiveness of the drug development process.

(i) Target Identification and Validation: AI has a significant impact on identifying potential biological targets and understanding their roles in diseases. This involves validating these targets to ensure they are involved in disease mechanisms and that modulating them could have therapeutic effects. AI analyzes genomic, proteomic, and metabolomic data to identify proteins or biological pathways associated with specific diseases. Machine learning algorithms sift through large datasets, providing researchers with valuable insights for drug development.



Figure 2: Drug Development Process: Target Deconvolution V/s Target Discovery



Figure 3: Virtual Screening ML Model in the Drug Development Process

Prediction of Drug Properties: AI algorithms can predict the physicochemical properties of drug candidates, such as solubility, permeability, and stability. These predictions are crucial for assessing the viability of drug candidates and can guide researchers in optimizing compounds for better performance. In summary, AI significantly enhances drug discovery through target identification and validation, virtual screening and drug design, and the prediction of drug properties, ultimately leading to faster and more efficient medication development.

(iv) Repositioning of Existing Drugs: AI in drug repositioning allows researchers to discover new uses for existing drugs by analyzing extensive databases that track drug-target interactions and disease pathways. This process, known as drug repurposing, can save considerable time and resources compared to developing new drugs from scratch. By leveraging existing knowledge about a drug's safety and efficacy, researchers can quickly test its effectiveness for new conditions.

In terms of drug combination identification, AI plays a crucial role in several ways:

1. Enhanced Synergy Detection: AI algorithms can analyze combinations of drugs to determine if they work better together than individually. This helps in identifying synergistic effects that can lead to more effective treatments.
2. Combination Optimization: AI can optimize drug combinations by evaluating various dosages and timing of administration. This ensures that the combined therapy is not only effective but also minimizes potential side effects.
3. Personalized Combination Therapies: AI can help tailor drug combinations to individual patients based on their genetic makeup, disease characteristics, and response to previous treatments. This personalized approach can improve treatment outcomes.
4. Prediction of Adverse Drug Interactions: AI can analyze historical data to predict potential adverse interactions between drugs in a combination therapy. This is vital for ensuring patient safety and avoiding harmful side effects.

Overall, AI significantly enhances the drug repositioning process and the identification of effective drug combinations, leading to more efficient and safer therapeutic options for patients.



Figure 4: Drug Repurposing Approach

AI Tool for Dosage Design:

The human body is indeed structured into various compartments to better understand how drugs are delivered and their effects. Each compartment is influenced by biological membranes, which serve as physicochemical barriers. These barriers are critical in determining how effectively a drug can be delivered based on its route of administration.

When a drug is taken orally, it first enters the gastric environment, and it is essential for it to permeate through the intestinal or gastric epithelium. This permeation is a crucial step for the drug to then enter the bloodstream and reach its target site, which could be specific tissues or cellular components.

Drugs can interact with intracellular molecules, which also serve as potential targets for drug entry. The process of drug permeation through biological barriers can occur either passively or actively. Passive diffusion relies on the molecular characteristics of the drug, while active permeation involves membrane transport mechanisms and is influenced by complex biological interactions.

In silico models are often utilized to predict drug distribution through computational analysis. However, these predictions may not always align

with actual studies of drug distribution in biological environments. The interaction of the drug with biological components and its availability significantly affect its behavior in the body.

For many biologically active substances and small molecules, passive permeation may not be sufficient, necessitating the development of specific drug delivery systems. Active permeation is more complex and requires careful exploration using various parameters through computational and systematic modeling approaches.

Pharmacokinetic parameters are essential in studying drug delivery systems, but one challenge in pharmaceutical research and development is the predictability of preclinical models. The assumptions made regarding predictability can sometimes lead to discrepancies between expected and actual outcomes in drug behavior.



Figure 5: AI Contribution to Drug Development and Research

Radiopharmaceutical Case Studies

ROLE OF AI IN PHARMA: AI has made significant strides in various aspects of healthcare, particularly in disease identification and drug discovery.

1. AI-based Disease Identification:

AI has shown remarkable potential in identifying infectious diseases. By analyzing vast amounts of data from various sources, such as electronic health records (EHRs), social media, and news reports, AI can quickly detect outbreaks of infectious diseases. This capability allows for the establishment of early warning systems that can alert health authorities and the public. Furthermore, AI can assist in predicting the spread of diseases by identifying high-risk populations and tracking the movement of infected individuals. The swift and precise data processing capabilities of AI greatly enhance our ability to recognize and respond to infectious disease threats.

2. Target Identification:

Target identification is a crucial step in the drug discovery process. Traditionally, this has involved time-consuming and costly experimental methods like high-throughput screening (HTS) and X-ray crystallography. However, AI has revolutionized this

area by enabling the identification of potential drug targets through computational methods. AI-based target identification utilizes machine learning (ML) algorithms to analyze large datasets, including gene expression profiles, protein-protein interaction networks, and biological pathways. This analysis generates a list of candidate targets, which can then be prioritized based on their relevance to specific diseases using algorithms such as support vector machines (SVMs) and neural networks.

3. AI-Enabled Virtual Screening in Drug Discovery:

The initial phase of drug discovery often involves the computational screening of numerous compounds to identify those that exhibit the desired cellular or biochemical effects. To improve the speed, efficiency, and cost-effectiveness of this process, new methods are continuously being developed. During the first round of screening, compounds that show a positive response in biochemical assays are identified as primary "hits." Following this, further screening is conducted to refine the selection of compounds for further development.

4. Predication of drug toxicity with AI:

The prediction of drug toxicity using AI is important because a significant number of drug candidates are discarded during clinical trials due to unexpected adverse effects. Accurately predicting drug toxicity in the preclinical stages is essential to lower the failure rate and enhance the efficiency of drug discovery.

Traditional methods for predicting drug toxicity often rely on small datasets and simple models, which can be limiting. In contrast, AI-based approaches offer promising alternatives by utilizing large and diverse data sources, such as chemical structures, biological pathways, and clinical data. By applying machine learning (ML) algorithms, these AI-based methods can improve the accuracy and efficiency of predicting the potentially toxic effects of new compounds. This can help reduce risks in clinical trials, lower drug development costs, and ultimately lead to better outcomes for patients.

Recently, there has been a growing popularity of AI-based computational models for forecasting drug toxicity. Many studies have analyzed large datasets of drugs and toxicity using ML and deep learning (DL) algorithms, like neural networks, to identify potential toxic effects during drug development. Early identification of toxicities can accelerate the development of new drugs. Moreover, AI-based toxicity prediction models can prioritize which compounds should be tested and discover new drug targets and toxicity mechanisms.

However, creating a single comprehensive review of AI-based toxicity prediction is challenging due to the vast range of toxicity properties involved. Therefore, there is a need for recent AI-based toxicity prediction models and detailed studies on toxicity properties to develop, optimize, and improve these models. Recent methods in ML and DL for predicting drug toxicity have been presented for four important toxicity properties.

5. The role of AI in rare disease research:

The role of AI in rare disease research is becoming increasingly important, as rare diseases (RDs) affect nearly 1 in 10 individuals in the US. Despite their prevalence, diagnosing RDs is often difficult due to the complexity of symptoms and the rarity of these conditions. In fact, the delay in diagnosis can take as long as 7 years, which leads to significant delays in treatment and management. This highlights the need for innovative approaches to improve the diagnosis and treatment of RDs.

AI has the potential to revolutionize the diagnosis and management of rare diseases through various machine learning and deep learning techniques, including Naive Bayes (NB), Random Forest (RF), XGBoost, Convolutional Neural Networks (CNN), Autoencoders (AE), Recurrent Neural Networks (RNN), and Generative Adversarial Networks (GAN).

For instance, a study by Fernández et al. developed a deep learning-based approach to detect tubers in specific MRI (magnetic resonance imaging) images for diagnosing tuberous sclerosis complex (TSC). This model utilized a unique InceptionV3 CNN architecture to determine whether an MRI image contained tubers, achieving an impressive accuracy of 95% in detecting this rare neurological disorder.

Additionally, Founta introduced a semi-automated preprocessing gene selection methodology to identify genes associated with amyotrophic lateral sclerosis (ALS). They developed a classifier based on XGBoost and RF, which successfully diagnosed ALS and its specific subtypes with an accuracy of 88.89% for classifying sporadic ALS motor neuron samples.Moreover, AI-based Positron Emission Tomography (PET) is emerging as a promising tool for the early detection and diagnosis of rare diseases. Overall, the integration of AI in rare disease research holds great potential for improving diagnosis and treatment outcomes.

Challenges of AI in Pharma:

There are several challenges in AI drug discovery that can hinder its effectiveness. Here are some key challenges:

1. Data Quality and Availability: AI models require high-quality data for proper training. However, in drug discovery, data is often sparse, noisy, or incomplete. Many datasets are not standardized, making it difficult for AI algorithms to learn effectively.

2. Complexity of Biological Systems: Biological systems are highly complex and often exhibit nonlinear relationships. This complexity makes it challenging for AI models to accurately predict how a drug will interact with various biological targets and pathways.

3. Interpretability: Many AI algorithms, especially deep learning models, operate as "black boxes," meaning their decision-making processes are not easily understood. This lack of transparency can be a

significant barrier in the pharmaceutical industry, as understanding the rationale behind predictions is crucial for regulatory approval.

4. Integration with Existing Processes: Integrating AI into traditional drug discovery workflows can be difficult. Many pharmaceutical companies have established processes that may not easily accommodate new AI technologies, leading to resistance or slow adoption.

5. Regulatory Challenges: The regulatory landscape for AI in drug discovery is still evolving. There is uncertainty about how regulatory bodies will evaluate AI-generated data, which can slow down development and approval processes.

6. Ethical Considerations: The use of AI in drug discovery raises ethical questions, particularly concerning data privacy and the potential for bias in AI algorithms. Ensuring that AI systems are fair and equitable is a significant concern.

7. Cost and Resource Requirements: Developing and implementing AI technologies can be costly and resource-intensive. Many smaller companies may lack the funding or expertise to effectively leverage AI in their drug discovery efforts.

CONCLUSION

The future of AI in drug discovery looks bright, with a focus on integrating automation. This means that AI systems could eventually make decisions about designing and synthesizing compounds without needing human input. This shift from a system where humans assist AI to one where AI operates independently could speed up the drug discovery process and provide better starting points for developing new drugs.

The ultimate goal is to create fully autonomous laboratories that can independently go through the cycle of designing, making, testing, and analyzing new drugs. Such advancements could lead to faster and more efficient drug discovery, with AI suggesting and testing new compounds on its own. However, there are still challenges to address, such as ensuring that the findings from AI systems are reliable and reproducible. Additionally, having access to strong datasets and investing in AI technology are crucial for the successful adoption of AI in drug discovery.

One of the biggest challenges in the medical industry when developing new drugs is the high costs and inefficiency associated with the process. Machine learning (ML) and recent advancements in deep learning (DL) offer great opportunities to lower these costs, improve efficiency, and save time in drug discovery and development. Although there are obstacles to incorporating AI tools into the drug discovery cycle, AI has already shown promising results. It has helped discover new material combinations, speed up the search for drug candidates, optimize drug formulations and delivery, improve target identification, and enhance virtual screening. Overall, the outlook for AI in drug discovery is encouraging, with expected advancements in autonomous decision-making and better integration with automation

REFERENCES

1. Chavda, V.; Valu, D.; Parikh, P.; Tiwari, N.; Chhipa, A.; Shukla, S.; Patel, S.; Balar, P.; Paiva-Santos, A.; Patravale, V. Conventional and Novel Diagnostic Tools for the Diagnosis of Emerging SARS-CoV-2 Variants. Vaccines 2023, 11, 374.
2. Sharma, R.; Shishodia, A.; Gunasekaran, A.; Min, H.; Munim, Z.H. The Role of Artificial Intelligence in Supply Chain Management: Mapping the Territory. Int. J. Prod. Res. 2022, 60, 7527–7550.
3. Kgmg. Available online: https://kpmg.com/xx/en/home/insights/2022/12/the-supply-chain-trends-shaking-up-2023.html (accessed on 2 May 2023).
4. A.A. Castro, T.D. Antonio, E.C. Martínez, et al., Usefulness of chest X-rays for evaluating prognosis in patients with COVID-19, Radiologia (English Edition) 63 (2021) 476-483.
5. W. Xie, F. Wang, Y. Li, et al., Advances and Challenges in De Novo Drug Design Using Three-Dimensional Deep Generative Models, Journal of Chemical Information and Modeling 62 (2022) 2269-2279.
6. W.T. Li, J. Ma, N. Shende, et al., Using machine learning of clinical data to diagnose COVID-19: a systematic review and meta-analysis, BMC medical informatics and decision making 20 (2020) 1-13.
7. A. Chatzigoulas, Z. Cournia, Rational design of allosteric modulators: Challenges and successes, WIREs Computational Molecular Science 11 (2021).
8. Q. Zhang, Y. Chen, D. Ni, et al., Targeting a cryptic allosteric site of SIRT6 with small-molecule inhibitors that inhibit the migration of pancreatic cancer cells, Acta Pharm Sin B 12 (2022) 876-889.
9. J.L. Causey, J. Zhang, S. Ma, et al., Highly accurate model for prediction of lung nodule malignancy with CT scans, Scientific reports 8 (2018) 9286.
10. Rudrapal, M.; Kirboga, K.K.; Abdalla, M.; Maji, S. Explainable artificial intelligence-assisted virtual screening and bioinformatics approaches for effective bioactivity prediction of phenolic cyclooxygenase-2 (COX-2) inhibitors using PubChem molecular fingerprints. Mol. Divers. 2024.
11. Briganti, G.; Le Moine, O. Artificial Intelligence in Medicine: Today and Tomorrow. Front. Med. 2020, 7, 27. Available online: https://www.frontiersin.org/articles/10.3389/fmed.2020.00027 (accessed on 20 October 2023).

12. Sohail, A. Genetic Algorithms in the Fields of Artificial Intelligence and Data Sciences. Ann. Data Sci. 2023, 10, 1007–1018.
13. Davis, C.R.; Murphy, K.J.; Curtis, R.G.; Maher, C.A. A Process Evaluation Examining the Performance, Adherence, and Acceptability of a Physical Activity and Diet Artificial Intelligence Virtual Health Assistant. Int. J. Environ. Res. Public Health 2020, 17, 9137.
14. Suprapto, S.; Nikmah, Y.L. Ridge and Lasso Regression for Feature Selection of Overlapping Ibuprofen and Paracetamol UV Spectra. Moroc. J. Chem. 2023, 11, 11–229.
15. Abdulhafedh, A. Comparison between Common Statistical Modeling Techniques Used in Research, Including: Discriminant Analysis vs Logistic Regression, Ridge Regression vs LASSO, and Decision Tree vs Random Forest. Open Access Libr. J. 2022, 9, 1–19.
16. Gong, D.; Ben-Akiva, E.; Singh, A.; Yamagata, H.; Est-Witte, S.; Shade, J.K.; Trayanova, N.A.; Green, J.J. Machine learning guided structure function predictions enable in silico nanoparticle screening for polymeric gene delivery. Acta Biomater. 2022, 154, 349–358.
17. Taye, M.M. Understanding of Machine Learning with Deep Learning: Architectures, Workflow, Applications and Future Directions. Computers 2023, 12, 91.
18. Friedman, R. Computational studies of protein–drug binding affinity changes upon mutations in the drug target. WIREs Comput. Mol. Sci. 2022, 12, e1563.
19. Varadharajan, V.; Arumugam, G.S.; Shanmugam, S. Isatin-based virtual high throughput screening, molecular docking, DFT, QM/MM, MD and MM-PBSA study of novel inhibitors of SARS-CoV-2 main protease. J. Biomol. Struct. Dyn. 2022, 40, 7852–7867.